Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Decreases By 44.0%

Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 43,800 shares, a decline of 44.0% from the November 15th total of 78,200 shares. Based on an average daily trading volume, of 48,900 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.2% of the company's shares are short sold.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Theratechnologies stock. National Bank of Canada FI increased its holdings in shares of Theratechnologies Inc. (NASDAQ:THTX - Free Report) by 29.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 186,815 shares of the company's stock after purchasing an additional 42,435 shares during the period. National Bank of Canada FI owned approximately 0.41% of Theratechnologies worth $232,000 at the end of the most recent quarter.

Theratechnologies Trading Down 0.8 %

NASDAQ:THTX traded down $0.01 on Thursday, reaching $1.44. 15,451 shares of the stock traded hands, compared to its average volume of 46,374. The firm has a market capitalization of $66.15 million, a price-to-earnings ratio of -14.50 and a beta of 1.43. Theratechnologies has a 1-year low of $1.08 and a 1-year high of $2.58. The company's 50 day moving average is $1.27 and its 200-day moving average is $1.31.

Theratechnologies (NASDAQ:THTX - Get Free Report) last announced its earnings results on Thursday, October 10th. The company reported $0.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.03. The firm had revenue of $22.60 million for the quarter. During the same period in the previous year, the company earned ($0.03) earnings per share. On average, equities research analysts forecast that Theratechnologies will post 0.03 EPS for the current fiscal year.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.